Stock listing
Frankfurt:4AB AbbVie Inc. Aktie
German listing (Frankfurt) of AbbVie Inc. · home listing NYSE:ABBV
Follow AbbVie Inc. into a list and get an email when it puts out news.
Share price · FWB:4AB
€262.80 EUR +2.70 (+1.0%)
Close on Nov 20, 2026
- Day range
- €258.60 – €262.80 EURNov 20, 2026
- Market cap
- €464.4B EURAt the close on Nov 20, 2026 · price × 1.77B shares outstanding
- 52-week range
- €165.93 – €270.62 EURLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- €192,974 EURMedian day 179 shares · 1 day with no trades · last 3 months, Aug 20, 2026 – Nov 6, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| NYSE:ABBV · Home | $286.20 USD | +0.19 (+0.1%) | 8,755,117 | $286.83 | $290.23 | $284.85 | $286.01 | Close on Nov 20, 2026 |
| TSX:ABBV | $39.79 CAD | +0.63 (+1.6%) | 15,795 | $39.79 | $40.14 | $39.68 | $39.16 | Close on Nov 20, 2026 |
| Xetra:4AB | €262.50 EUR | +5.90 (+2.3%) | 211 | €260.90 | €263.70 | €258.70 | €256.60 | Close on Nov 20, 2026 |
| Cboe Canada:ABBV | $39.91 CAD | +0.45 (+1.1%) | 100 | $39.91 | $39.91 | $39.91 | $39.46 | Close on Nov 20, 2026 |
| B3:ABBV34 | 105.62 BRL | +0.15 (+0.1%) | 1,953 | 103.90 | 105.62 | 103.50 | 105.47 | Close on Nov 19, 2026 |
| BMV:ABBV | $5,537.00 MXN | +134.00 (+2.5%) | 75 | $5,537.00 | $5,537.00 | $5,537.00 | $5,403.00 | Close on Nov 20, 2026 |
| Frankfurt:4AB | €262.80 EUR | +2.70 (+1.0%) | — | €259.20 | €262.80 | €258.60 | €260.10 | Close on Nov 20, 2026 |
| Stuttgart:4AB | €260.80 EUR | +2.60 (+1.0%) | 21 | €258.00 | €263.70 | €258.00 | €258.20 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 6, 2026 · FWB:4AB · EUR, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| €258.34 | +1.104 | +0.4% | €256.57 | €262.84 | €251.52 | 57 | |
| €257.23 | +2.075 | +0.8% | €264.77 | €268.44 | €257.22 | 774 | |
| €255.16 | -5.365 | -2.1% | €252.43 | €261.15 | €252.35 | 4,534 | |
| €260.52 | +3.985 | +1.6% | €258.89 | €260.66 | €257.85 | 178 | |
| €256.54 | -7.30 | -2.8% | €259.57 | €264.26 | €256.48 | 615 | |
| €263.84 | +4.603 | +1.8% | €261.42 | €270.62 | €252.28 | 6,958 | |
| €259.23 | +4.304 | +1.7% | €258.99 | €260.03 | €256.54 | 5,852 | |
| €254.93 | -0.733 | -0.3% | €255.43 | €257.24 | €253.34 | 529 | |
| €255.66 | +0.688 | +0.3% | €256.01 | €256.09 | €254.54 | 135 | |
| €254.97 | +0.125 | 0.0% | €255.17 | €260.63 | €254.37 | 100 | |
| €254.85 | +0.168 | +0.1% | €255.15 | €255.15 | €253.44 | 164 | |
| €254.68 | +0.409 | +0.2% | €250.11 | €258.84 | €249.34 | 209 | |
| €254.27 | -3.293 | -1.3% | €252.88 | €257.83 | €251.95 | 295 | |
| €257.57 | +2.069 | +0.8% | €256.65 | €257.58 | €256.02 | 179 | |
| €255.50 | +5.958 | +2.4% | €255.32 | €255.78 | €254.24 | 30 | |
| €249.54 | -8.111 | -3.1% | €253.34 | €254.61 | €249.02 | 0 | |
| €257.65 | +14.47 | +6.0% | €253.36 | €261.66 | €251.17 | 555 | |
| €243.18 | -7.171 | -2.9% | €243.18 | €243.18 | €243.18 | 540 | |
| €250.35 | +0.638 | +0.3% | €252.05 | €254.93 | €247.43 | 344 | |
| €249.71 | +3.999 | +1.6% | €247.93 | €250.50 | €247.57 | 360 | |
| €245.71 | +8.048 | +3.4% | €243.04 | €246.31 | €241.85 | 2,598 | |
| €237.66 | -5.36 | -2.2% | €239.32 | €242.71 | €235.39 | 117 | |
| €243.02 | +5.962 | +2.5% | €236.84 | €247.36 | €235.25 | 265 | |
| €237.06 | +1.618 | +0.7% | €237.04 | €237.13 | €236.95 | 262 | |
| €235.44 | +3.928 | +1.7% | €235.55 | €236.56 | €235.28 | 23 | |
| €231.51 | +2.998 | +1.3% | €229.84 | €234.14 | €229.36 | 320 | |
| €228.52 | -1.72 | -0.7% | €228.52 | €228.52 | €228.52 | 74 | |
| €230.24 | -3.248 | -1.4% | €230.24 | €230.24 | €230.24 | 1 | |
| €233.48 | -1.365 | -0.6% | €234.20 | €234.37 | €233.48 | 1 | |
| €234.85 | +5.213 | +2.3% | €234.44 | €235.14 | €234.02 | 150 | |
| €229.64 | -2.165 | -0.9% | €230.60 | €234.10 | €229.39 | 2,224 | |
| €231.80 | -0.204 | -0.1% | €232.00 | €233.60 | €230.93 | 50 | |
| €232.01 | +2.462 | +1.1% | €233.31 | €233.42 | €230.28 | 796 | |
| €229.54 | -2.805 | -1.2% | €229.54 | €229.54 | €229.54 | 90 | |
| €232.35 | +1.126 | +0.5% | €232.35 | €232.35 | €232.35 | 109 | |
| €231.22 | +2.762 | +1.2% | €231.15 | €233.27 | €230.96 | 3,714 | |
| €228.46 | +1.892 | +0.8% | €228.46 | €228.46 | €228.46 | 38 | |
| €226.57 | -0.584 | -0.3% | €226.83 | €227.73 | €225.76 | 132 | |
| €227.15 | +2.339 | +1.0% | €227.09 | €227.45 | €223.86 | 15 | |
| €224.81 | +4.237 | +1.9% | €220.28 | €228.29 | €219.90 | 284 | |
| €220.58 | +6.528 | +3.0% | €216.96 | €221.16 | €216.61 | 40 | |
| €214.05 | -0.118 | -0.1% | €213.93 | €214.06 | €212.99 | 405 | |
| €214.17 | -3.823 | -1.8% | €212.52 | €216.64 | €211.27 | 5 | |
| €217.99 | -1.696 | -0.8% | €217.99 | €217.99 | €217.99 | 261 | |
| €219.69 | -1.724 | -0.8% | €219.69 | €219.69 | €219.69 | 2 | |
| €221.41 | -2.687 | -1.2% | €222.15 | €222.15 | €220.28 | 552 | |
| €224.10 | +0.279 | +0.1% | €224.10 | €224.10 | €224.10 | 47 | |
| €223.82 | +2.748 | +1.2% | €223.04 | €223.83 | €221.97 | 58 | |
| €221.07 | +1.791 | +0.8% | €221.07 | €221.07 | €221.07 | 211 | |
| €219.28 | -1.893 | -0.9% | €219.28 | €219.28 | €219.28 | 1 | |
| €221.17 | -1.617 | -0.7% | €221.56 | €221.57 | €221.17 | 441 | |
| €222.79 | -7.385 | -3.2% | €225.74 | €226.46 | €221.42 | 208 | |
| €230.17 | +5.372 | +2.4% | €230.17 | €230.17 | €230.17 | 17 | |
| €224.80 | -2.313 | -1.0% | €227.00 | €228.67 | €223.94 | 20 | |
| €227.11 | +1.833 | +0.8% | €223.80 | €228.50 | €223.75 | 191 | |
| €225.28 | -1.581 | -0.7% | €222.08 | €225.87 | €221.35 | 8,912 | |
| €226.86 | +3.027 | +1.4% | €230.69 | €230.69 | €226.35 | 47 |
- Ticker
- Frankfurt:4AB
- Asset type
- Stock
- Sector
- Health care
- Industry
- Pharmaceuticals
- Exchange
- Frankfurt
- Currency
- EUR
What changed lately
Latest news release · Nov 20, 2026
AbbVie to Present at the Piper Sandler 38th Annual Healthcare Conference
Latest earnings call · Oct 30, 2026
AbbVie (NYSE:ABBV) Q3 2026 Earnings Call
Replay and transcript
Latest deck · Jun 22, 2026
Merger or Acquisition (June 2026)
Merger or acquisition · 15 slides
Latest news
ABBV 3Q26 Press Release Final
Oct 30, 2026
Closed €263.84 (+1.8%) on Oct 30, 2026
AbbVie Reports Third-Quarter 2026 Financial Results
Oct 30, 2026
Closed €263.84 (+1.8%) on Oct 30, 2026
AbbVie TEMPLE Study Demonstrates Superior Tolerability and Efficacy of Atogepant (QULIPTA®) in Head-to-Head Migraine Prevention Trial
Oct 29, 2026
Closed €259.23 (+1.7%) on Oct 29, 2026
The Countdown Is On: BOTOX® Cosmetic (onabotulinumtoxinA) Day is Back Nov. 18
Oct 28, 2026
Closed €254.93 (-0.3%) on Oct 28, 2026
Allergan Aesthetics Announces 2026 Grant Recipients of The Confidence Collective, Funded by BOTOX® Cosmetic (onabotulinumtoxinA)
Oct 27, 2026
Closed €255.66 (+0.3%) on Oct 27, 2026
AbbVie Submits Biologics License Application (BLA) for Etentamig to U.S. FDA for Adults Living With Relapsed/Refractory Multiple Myeloma
Oct 27, 2026
Closed €255.66 (+0.3%) on Oct 27, 2026
AbbVie Inc. on 6ix
- Sector
- Health care
- Industry
- Pharmaceuticals
- News releases
- 140 in the last 12 months · 191 in all · newest Nov 20, 2026 · oldest 2025
- Calls
- 32 calls with a replay · 32 with a transcript · latest Oct 30, 2026
- Decks
- 33 decks · latest Jun 22, 2026
Where AbbVie Inc. is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| NYSE:ABBV · Home listing | NYSE | United States | USD |
| gettex:4AB | gettex | Germany | EUR |
| BCBA:ABBV | BCBA | Argentina | ARS |
| SET:ABBV19 | SET | Thailand | THB |
| Tradegate:4AB | Tradegate | Germany | EUR |
| TSX:ABBV | TSX | Canada | CAD |
| Xetra:4AB | Xetra | Germany | EUR |
| Cboe Canada:ABBV | Cboe Canada | Canada | CAD |
| B3:ABBV34 | B3 | Brazil | BRL |
| SET:ABBV80 | SET | Thailand | THB |
| LS Exchange:A1J84E | LS Exchange | Germany | EUR |
| BMV:ABBV | BMV | Mexico | MXN |
| Milan:1ABBV | Milan | Italy | EUR |
| BCBA:ABBVD | BCBA | Argentina | USD |
| LSIN:0QCV | LSIN | United Kingdom | USD |
| EUROTLX:4ABBV | EUROTLX | Italy | EUR |
| Frankfurt:4AB · This page | Frankfurt | Germany | EUR |
| Lang & Schwarz:A1J84E | Lang & Schwarz | Germany | EUR |
| SIX Swiss:ABBV | SIX Swiss | Switzerland | CHF |
| Stuttgart:4AB | Stuttgart | Germany | EUR |
| BIVA:ABBV | BIVA | Mexico | MXN |
| BCBA:ABBVC | BCBA | Argentina | USD |
| BOATS:ABBV | BOATS | United States | USD |
| VIE:ABBV | Vienna | Austria | EUR |
| Munich:4AB | Munich | Germany | EUR |
| BCS:ABBV | BCS | Chile | USD |
| Dusseldorf:4AB | Dusseldorf | Germany | EUR |
| BX Swiss:4AB | BX Swiss | Switzerland | CHF |
| Hamburg:4AB | Hamburg | Germany | EUR |
| BSESOF:4AB | BSESOF | Bulgaria | EUR |
| Dusseldorf:4AB0 | Dusseldorf | Germany | EUR |
| Frankfurt:4AB0 | Frankfurt | Germany | EUR |
| SIX Swiss:ABBV.USD | SIX Swiss | Switzerland | USD |
| BCS:ABBVCL | BCS | Chile | CLP |
| Turquoise:4ABD | Turquoise | United Kingdom | EUR |
| BCBA:ABBV.CI | BCBA | Argentina | ARS |
| Hanover:4AB | Hanover | Germany | EUR |
Valuation
P/E 48.9× against a median of 28.8×: 10th lowest of 11 Pharmaceuticals companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026
- Enterprise value
- $503.8B USD
- P/E
- 48.9×
- EV/sales
- 7.6×
- EV/EBITDA
- No depreciation figure on 6ix yet
- Price/book
- Negative equity
- Gross margin
- 73.7%
- Operating margin
- Not reported
- Net margin
- 15.7%
- Debt to equity
- Negative equity
- Beta vs S&P 500
- 0.00
Pharmaceuticals: the 10 companies nearest in size, of 492 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| AbbVie Inc. · NYSE:ABBV | US$505.9B | US$503.8B | 48.9× | 7.6× | n/a | n/a | 15.7% | n/a | 0.00 |
| Eli Lilly and Company · NYSE:LLY | US$1.27T | US$1.31T | 46.0× | 15.1× | n/a | 31.5× | 31.9% | 1.2× | 0.34 |
| Johnson & Johnson · NYSE:JNJ | US$651.1B | US$678.5B | 40.5× | 6.8× | n/a | 8.0× | 16.2% | 0.6× | -0.02 |
| Merck & Company, Inc. · NYSE:MRK | US$329.7B | US$373.8B | 134× | 5.5× | n/a | 7.3× | 3.6% | 1.2× | 0.28 |
| Novartis AG · SIX:NOVN | US$287.4B | US$304.7B | 20.6× | n/a | n/a | 6.2× | n/a | 0.6× | n/a |
| AstraZeneca PLC · LSE:AZN | US$272.1B | US$298.0B | 24.6× | 4.8× | 14.1× | 5.3× | 17.7% | 0.7× | n/a |
| Pfizer, Inc. · NYSE:PFE | US$156.2B | US$207.8B | 38.7× | 3.3× | 9.6× | 1.8× | 6.3% | 0.7× | 0.29 |
| Vertex Pharmaceuticals Incorporated · NASDAQ:VRTX | US$130.6B | US$128.8B | 32.8× | 9.9× | 28.4× | 6.3× | 30.7% | 0.2× | 0.47 |
| Novo Nordisk A/S Class B · OMXCOP:NOVO_B | US$129.4B | US$142.3B | 7.8× | 2.9× | 5.5× | 4.0× | 33.9% | 0.6× | n/a |
| Bristol-Myers Squibb Company · NYSE:BMY | US$120.2B | US$151.3B | 13.0× | 3.0× | n/a | 5.1× | 18.5% | 1.9× | 0.26 |
| Sanofi SA · EURONEXT:SAN | US$111.7B | US$126.9B | 14.6× | 2.3× | 4.7× | 1.4× | 13.9% | 0.3× | n/a |
| Median of the others | US$214.1B | US$252.9B | 28.8× | 4.8× | 9.6× | 5.8× | 17.7% | 0.6× | 0.29 |
Forecasts
16 strong buy · 7 buy · 5 hold · 1 sell · Analysts' consensus from EODHD, read Nov 22, 2026. Not 6ix's view and not investment advice.
- Price target
- 315.88 USD · Analysts' mean
- EPS, year to Dec 2026
- 13.98 · 29 analysts
- Revenue, year to Dec 2026
- 67.79B · 26 analysts
Team and board
Officers
| Officer | Role |
|---|---|
| Robert A. Michael | Chairman of the Board and Chief Executive Officer |
| Brett J. Hart | President |
| Roxanne S. Austin | President |
| Adelle Infante | Corporate Communications |
Board
| Director | Role |
|---|---|
| Robert A. Michael | Chairman of the Board and Chief Executive Officer |
| William H.L. Burnside | Director |
Events
Calls
| Call | When | Status |
|---|---|---|
| AbbVie (NYSE:ABBV) Q3 2026 Earnings Call | Fri, Oct 30, 2026 · 9:00 AM ET | Replay |
| AbbVie (NYSE:ABBV) Q2 2026 Earnings Call | Fri, Jul 31, 2026 · 9:00 AM ET | Replay |
| AbbVie (NYSE:ABBV) Q1 2026 Earnings Call | Wed, Apr 29, 2026 · 9:00 AM ET | Replay |
| AbbVie (NYSE:ABBV) Q4 2025 Earnings Call | Wed, Feb 04, 2026 · 9:00 AM ET | Replay |
| AbbVie (NYSE:ABBV) Q3 2025 Earnings Call | Fri, Oct 31, 2025 · 9:00 AM ET | Replay |
| AbbVie (NYSE:ABBV) Q2 2025 Earnings Call | Thu, Jul 31, 2025 · 9:00 AM ET | Replay |
| AbbVie (NYSE:ABBV) Q1 2025 Earnings Call | Fri, Apr 25, 2025 · 9:00 AM ET | Replay |
| AbbVie (NYSE:ABBV) Q4 2024 Earnings Call | Fri, Jan 31, 2025 · 9:00 AM ET | Replay |
| AbbVie (NYSE:ABBV) Q3 2024 Earnings Call | Wed, Oct 30, 2024 · 9:00 AM ET | Replay |
| AbbVie (NYSE:ABBV) Q2 2024 Earnings Call | Thu, Jul 25, 2024 · 9:00 AM ET | Replay |
All 32 calls
Results days
| Quarter | Results | Share move |
|---|---|---|
| Q3 2026 | Oct 30, 2026 · Before open | +1.4% |
| Q2 2026 | Jul 31, 2026 · Before open | −2.5% |
| Q1 2026 | Apr 29, 2026 · Before open | +3.1% |
| Q4 2025 | Feb 4, 2026 · Before open | −3.8% |
| Q3 2025 | Oct 31, 2025 · Before open | −4.5% |
| Q2 2025 | Jul 31, 2025 · Before open | −0.1% |
| Q1 2025 | Apr 25, 2025 · Before open | +3.1% |
| Q4 2024 | Jan 31, 2025 · Before open | +4.7% |
| Q3 2024 | Oct 30, 2024 · Before open | +6.4% |
| Q2 2024 | Jul 25, 2024 · Before open | +3.4% |
All 20 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q1 2024 | Apr 26, 2024 · Before open | −4.6% |
| Q4 2023 | Feb 2, 2024 · Before open | +0.6% |
| Q3 2023 | Oct 27, 2023 · Before open | −4.3% |
| Q2 2023 | Jul 27, 2023 · Before open | +4.9% |
| Q1 2023 | Apr 27, 2023 · Before open | −8.0% |
| Q4 2022 | Feb 9, 2023 · Before open | +2.8% |
| Q3 2022 | Oct 28, 2022 · Before open | −3.8% |
| Q2 2022 | Jul 29, 2022 · Before open | −4.2% |
| Q1 2022 | Apr 29, 2022 · Before open | −6.0% |
| Q4 2021 | Feb 2, 2022 · Before open | +1.2% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Merger or Acquisition (June 2026) | Merger or acquisition | 15 slides | Jun 22, 2026 |
| Q4 2025 Earnings Presentation | Earnings | 4 slides | Feb 4, 2026 |
| Q1 2025 Earnings Presentation | Earnings | 9 slides | Apr 25, 2025 |
| Fact Sheet (2025) | Fact sheet | 6 slides | 2025 |
| Investor Presentation (2024) | Investor deck | 21 slides | May 2, 2024 |
| Investor Presentation (2024) | Investor deck | 21 slides | 2024 |
| Merger or Acquisition (December 2023) | Merger or acquisition | 14 slides | Dec 6, 2023 |
| Merger or Acquisition (November 2023) | Merger or acquisition | 14 slides | Nov 30, 2023 |
| Q3 2023 Earnings Presentation | Earnings | 13 slides | Oct 27, 2023 |
| Fact Sheet (August 2023) | Fact sheet | 1 slide | August 2023 |
All 33 decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Q4 2022 Earnings Presentation | Earnings | 4 slides | Feb 9, 2023 |
| J.P. Morgan Healthcare Conference 2023 | Conference | 20 slides | Jan 10, 2023 |
| Investor Presentation (2022) | Investor deck | 35 slides | Jun 6, 2022 |
| Q4 2021 Earnings Presentation | Earnings | 4 slides | Feb 2, 2022 |
| Fact Sheet (February 2022) | Fact sheet | 1 slide | February 2022 |
| J.P. Morgan Healthcare Conference 2022 | Conference | 21 slides | Jan 11, 2022 |
| Fact Sheet (September 2021) | Fact sheet | 1 slide | September 2021 |
| J.P. Morgan Healthcare Conference 2021 | Conference | 21 slides | Jan 12, 2021 |
| Fact Sheet (November 2020) | Fact sheet | 1 slide | Nov 26, 2020 |
| Investor Day (March 2020) | Investor day | 122 slides | Mar 10, 2020 |
| Merger or Acquisition (June 2019) | Merger or acquisition | 28 slides | Jun 25, 2019 |
| Jefferies Healthcare Conference 2018 | Conference | 11 slides | Jun 6, 2018 |
| J.P. Morgan Healthcare Conference 2018 | Conference | 20 slides | Jan 10, 2018 |
| Jefferies Healthcare Conference 2017 | Conference | 9 slides | Jun 8, 2017 |
| J.P. Morgan Healthcare Conference 2017 | Conference | 18 slides | Jan 11, 2017 |
| J.P. Morgan Healthcare Conference 2016 | Conference | 16 slides | Jan 13, 2016 |
| Investor Day (October 2015) | Investor day | 33 slides | Oct 30, 2015 |
| Investor Presentation (2015) | Investor deck | 8 slides | Sep 6, 2015 |
| Merger or Acquisition (March 2015) | Merger or acquisition | 20 slides | Mar 5, 2015 |
| Fact Sheet (January 2015) | Fact sheet | 6 slides | January 2015 |
| Merger or Acquisition (June 2014) | Merger or acquisition | 40 slides | Jun 25, 2014 |
| J.P. Morgan Healthcare Conference 2013 | Conference | 17 slides | Jan 8, 2013 |
| Investor Presentation | Investor deck | 22 slides |
Financials
Annual, in USD
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 61.2B | 56.3B | 54.3B | 58.1B | 56.2B | 45.8B | 33.3B | 32.8B | 28.2B | 25.6B |
| Cost of revenue | 18.2B | 16.9B | 20.4B | 17.4B | 17.4B | 15.4B | 7.44B | 7.72B | 7.04B | 5.83B |
| Gross profit | 43.0B | 39.4B | 33.9B | 40.6B | 38.8B | 30.4B | 25.8B | 25.0B | 21.2B | 19.8B |
| Research and development | 9.10B | 12.8B | 7.67B | 6.51B | 6.92B | 6.38B | 6.41B | 10.3B | 5.01B | 4.38B |
| Selling, general and administrative | 14.0B | 14.8B | 12.9B | 15.3B | 12.3B | 11.3B | 6.94B | 7.40B | 6.29B | 5.88B |
| Operating income | 15.1B | 9.14B | 12.8B | 18.1B | 17.9B | 11.4B | 13.0B | 6.38B | 9.54B | 9.34B |
| Depreciation and amortization | 762.0M | 764.0M | 752.0M | 778.0M | 803.0M | 666.0M | 464.0M | 471.0M | 425.0M | 425.0M |
| EBITDA | 15.8B | 9.90B | 13.5B | 18.9B | 18.7B | 12.0B | 13.4B | 6.85B | 9.97B | 9.77B |
| Interest expense | 2.89B | 2.81B | 2.22B | 2.23B | 2.42B | 2.45B | 1.78B | 1.35B | 1.15B | 1.05B |
| Income before tax | 6.60B | 3.72B | 6.25B | 13.5B | 13.0B | 3.40B | 8.43B | 5.20B | 7.73B | 7.88B |
| Income tax | 2.36B | -570.0M | 1.38B | 1.63B | 1.44B | -1.22B | 544.0M | -490.0M | 2.42B | 1.93B |
| Net income | 4.23B | 4.28B | 4.86B | 11.8B | 11.5B | 4.62B | 7.88B | 5.69B | 5.31B | 5.95B |
| Earnings per share, basic | 2.37 | 2.40 | 2.73 | 6.65 | 6.48 | 2.73 | 5.30 | 3.67 | 3.31 | 3.65 |
| Earnings per share, diluted | 2.36 | 2.39 | 2.72 | 6.63 | 6.45 | 2.72 | 5.28 | 3.66 | 3.30 | 3.63 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 5.23B | 5.52B | 12.8B | 9.20B | 9.75B | 8.45B | 39.9B | 7.29B | 9.30B | 5.10B |
| Short-term investments | 28.0M | 31.0M | 2.00M | 28.0M | 84.0M | 30.0M | 0 | 772.0M | 486.0M | 1.32B |
| Receivables | 12.6B | 10.9B | 11.2B | 11.3B | 9.98B | 8.82B | 5.43B | 5.38B | 5.09B | 4.76B |
| Inventory | 4.95B | 4.18B | 4.10B | 3.58B | 3.13B | 3.31B | 1.81B | 1.60B | 1.60B | 1.44B |
| Current assets | 29.1B | 25.6B | 33.0B | 28.5B | 27.9B | 24.2B | 49.5B | 16.9B | 21.2B | 16.2B |
| Property, plant and equipment | 5.63B | 5.13B | 4.99B | 4.93B | 5.11B | 5.25B | 2.96B | 2.88B | 2.80B | 2.60B |
| Goodwill | 35.6B | 35.0B | 32.3B | 32.2B | 32.4B | 33.1B | 15.6B | 15.7B | 15.8B | 15.4B |
| Total assets | 134.0B | 135.2B | 134.7B | 138.8B | 146.5B | 150.6B | 89.1B | 59.4B | 70.8B | 66.1B |
| Accounts payable | 3.59B | 2.94B | 3.69B | 2.93B | 2.88B | 2.28B | 1.45B | 1.55B | 1.47B | 1.41B |
| Current liabilities | 43.3B | 38.7B | 37.8B | 29.5B | 35.2B | 28.7B | 15.6B | 17.2B | 16.6B | 9.78B |
| Long-term debt | 58.9B | 60.3B | 52.2B | 59.1B | 64.2B | 77.6B | 63.0B | 35.0B | 31.0B | 36.4B |
| Total debt | 67.0B | 66.8B | 59.2B | 63.1B | 76.0B | 85.0B | 67.2B | 5.31B | 6.42B | 402.0M |
| Shareholders' equity | -3.27B | 3.33B | 10.4B | 17.3B | 15.4B | 13.1B | -8.17B | -8.45B | 5.10B | 4.64B |
| Shares outstanding | 1.77B | 1.77B | 1.77B | 1.77B | 1.77B | 1.77B | 1.77B | 1.77B | 1.48B | 1.48B |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | 19.0B | 18.8B | 22.8B | 24.9B | 22.8B | 17.6B | 13.3B | 13.4B | 9.96B | 7.04B |
| Capital spending | -1.21B | -974.0M | -777.0M | -695.0M | -787.0M | -798.0M | -552.0M | -638.0M | -529.0M | -479.0M |
| Free cash flow | 17.8B | 17.8B | 22.1B | 24.2B | 22.0B | 16.8B | 12.8B | 12.8B | 9.43B | 6.56B |
| Cash from investing | -6.64B | -20.8B | -2.01B | -623.0M | -2.34B | -37.6B | 596.0M | -1.01B | -274.0M | -6.07B |
| Cash from financing | -12.7B | -5.21B | -17.2B | -24.8B | -19.0B | -11.5B | 18.7B | -14.4B | -5.51B | -3.93B |
| Dividends paid | -11.7B | -11.0B | -10.5B | -10.0B | -9.26B | -7.72B | -6.37B | -5.58B | -4.11B | -3.72B |
| Share buybacks | -980.0M | -1.71B | -1.97B | -1.49B | -934.0M | -978.0M | -629.0M | -12.0B | -1.41B | -6.03B |
| Change in cash | -295.0M | -7.29B | 3.61B | -545.0M | 1.30B | -31.5B | 32.6B | -2.01B | 4.20B | -3.30B |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 4 · Change in ownership | Nov 18, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Nov 16, 2026 | Other filings | SEC |
| 4 · Change in ownership | Nov 12, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Nov 9, 2026 | Other filings | SEC |
| 10-Q · Quarterly report | Nov 3, 2026 | Quarterly report | SEC |
| 8-K · Current report | Nov 2, 2026 | Management or board change | SEC |
| 8-K · Current report | Oct 30, 2026 | Results | SEC |
| 3 · Initial statement of ownership | Oct 23, 2026 | Insider trade | SEC |
| 8-K · Current report | Oct 15, 2026 | Management or board change | SEC |
| 8-K · Current report | Oct 5, 2026 | Results | SEC |
Show 200 filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 4 · Change in ownership | Oct 2, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Oct 2, 2026 | Insider trade | SEC |
| 8-K · Current report | Sep 3, 2026 | Current report | SEC |
| 4 · Change in ownership | Aug 18, 2026 | Insider trade | SEC |
| 8-K · Current report | Aug 18, 2026 | Current report | SEC |
| 144 · Notice of proposed sale | Aug 14, 2026 | Other filings | SEC |
| 424B5 · Prospectus | Aug 6, 2026 | Offer document | SEC |
| 8-K · Current report | Aug 5, 2026 | Current report | SEC |
| FWP · Free writing prospectus | Aug 4, 2026 | Offer document | SEC |
| 424B5 · Prospectus | Aug 4, 2026 | Offer document | SEC |
| 10-Q · Quarterly report | Aug 3, 2026 | Quarterly report | SEC |
| 8-K · Current report | Jul 31, 2026 | Results | SEC |
| 8-K · Current report | Jul 6, 2026 | Results | SEC |
| 4 · Change in ownership | Jul 2, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jul 2, 2026 | Insider trade | SEC |
| 11-K · Annual report of an employee plan | Jun 24, 2026 | Annual report | SEC |
| 8-K · Current report | Jun 22, 2026 | Current report | SEC |
| SD · Specialized disclosure | Jun 1, 2026 | ESG report | SEC |
| 144 · Notice of proposed sale | May 26, 2026 | Other filings | SEC |
| 8-K · Current report | May 12, 2026 | Meeting outcome | SEC |
| 4 · Change in ownership | May 12, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 12, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 12, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 12, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 12, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 12, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 12, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 12, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 12, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 12, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 12, 2026 | Insider trade | SEC |
| 10-Q · Quarterly report | May 8, 2026 | Quarterly report | SEC |
| SCHEDULE 13G · Big-stake notice | Apr 29, 2026 | Big-stake notice | SEC |
| 8-K · Current report | Apr 29, 2026 | Results | SEC |
| 8-K · Current report | Apr 3, 2026 | Results | SEC |
| 4 · Change in ownership | Apr 2, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Apr 2, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Apr 2, 2026 | Insider trade | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Mar 26, 2026 | Big-stake notice | SEC |
| ARS · Annual report to shareholders | Mar 23, 2026 | Annual report | SEC |
| DEFA14A · Additional proxy material | Mar 23, 2026 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Mar 23, 2026 | Meeting notice | SEC |
| 4/A · Change in ownership, amended | Mar 11, 2026 | Insider trade | SEC |
| PRE 14A · Preliminary proxy statement | Mar 9, 2026 | Meeting notice | SEC |
| 4 · Change in ownership | Mar 6, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Mar 6, 2026 | Other filings | SEC |
| 4 · Change in ownership | Mar 6, 2026 | Insider trade | SEC |
| 8-K · Current report | Mar 4, 2026 | Current report | SEC |
| 4 · Change in ownership | Mar 3, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 3, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 3, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 3, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 3, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 3, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 3, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 3, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Mar 2, 2026 | Other filings | SEC |
| 4 · Change in ownership | Feb 27, 2026 | Insider trade | SEC |
| 8-K · Current report | Feb 26, 2026 | Current report | SEC |
| 424B5 · Prospectus | Feb 26, 2026 | Offer document | SEC |
| FWP · Free writing prospectus | Feb 26, 2026 | Offer document | SEC |
| 144 · Notice of proposed sale | Feb 25, 2026 | Other filings | SEC |
| FWP · Free writing prospectus | Feb 24, 2026 | Offer document | SEC |
| 424B5 · Prospectus | Feb 24, 2026 | Offer document | SEC |
| 4 · Change in ownership | Feb 20, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 20, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 20, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 20, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 20, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 20, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 20, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 20, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 20, 2026 | Insider trade | SEC |
| 10-K · Annual report | Feb 20, 2026 | Annual report | SEC |
| 8-K · Current report | Feb 4, 2026 | Results | SEC |
| 8-K · Current report | Jan 7, 2026 | Results | SEC |
| 4 · Change in ownership | Jan 5, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 5, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 5, 2026 | Insider trade | SEC |
| 10-Q · Quarterly report | Nov 4, 2025 | Quarterly report | SEC |
| 8-K · Current report | Oct 31, 2025 | Results | SEC |
| 8-K · Current report | Oct 3, 2025 | Results | SEC |
| 4 · Change in ownership | Oct 2, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Oct 2, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Oct 2, 2025 | Insider trade | SEC |
| 8-K · Current report | Sep 11, 2025 | Current report | SEC |
| 144 · Notice of proposed sale | Aug 22, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Aug 21, 2025 | Other filings | SEC |
| 4 · Change in ownership | Aug 14, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Aug 12, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Aug 8, 2025 | Other filings | SEC |
| 4 · Change in ownership | Aug 7, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Aug 5, 2025 | Other filings | SEC |
| 10-Q · Quarterly report | Aug 4, 2025 | Quarterly report | SEC |
| 8-K · Current report | Jul 31, 2025 | Results | SEC |
| 3/A · Initial statement of ownership, amended | Jul 30, 2025 | Insider trade | SEC |
| 3 · Initial statement of ownership | Jul 11, 2025 | Insider trade | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Jul 7, 2025 | Big-stake notice | SEC |
| 8-K · Current report | Jul 3, 2025 | Results | SEC |
| 4 · Change in ownership | Jul 2, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jul 2, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jul 2, 2025 | Insider trade | SEC |
| 11-K · Annual report of an employee plan | Jun 13, 2025 | Annual report | SEC |
| SD · Specialized disclosure | May 30, 2025 | ESG report | SEC |
| 4 · Change in ownership | May 13, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 13, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 13, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 13, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 13, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 13, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 13, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 13, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 13, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 13, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 13, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 13, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 13, 2025 | Insider trade | SEC |
| 3 · Initial statement of ownership | May 13, 2025 | Insider trade | SEC |
| 8-K · Current report | May 12, 2025 | Management or board change | SEC |
| 10-Q · Quarterly report | May 9, 2025 | Quarterly report | SEC |
| 8-K · Current report | Apr 25, 2025 | Results | SEC |
| 8-K · Current report | Apr 3, 2025 | Results | SEC |
| 4 · Change in ownership | Apr 2, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Apr 2, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Apr 2, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Apr 2, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Apr 2, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Mar 31, 2025 | Other filings | SEC |
| ARS · Annual report to shareholders | Mar 24, 2025 | Annual report | SEC |
| DEFA14A · Additional proxy material | Mar 24, 2025 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Mar 24, 2025 | Meeting notice | SEC |
| 4 · Change in ownership | Mar 18, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Mar 14, 2025 | Other filings | SEC |
| PRE 14A · Preliminary proxy statement | Mar 10, 2025 | Meeting notice | SEC |
| 3 · Initial statement of ownership | Mar 10, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 4, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 4, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 4, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 4, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 4, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 4, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 4, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 4, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 4, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 4, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Mar 3, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Mar 3, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Mar 3, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Feb 28, 2025 | Other filings | SEC |
| 4 · Change in ownership | Feb 28, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 28, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Feb 28, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Feb 26, 2025 | Other filings | SEC |
| 8-K · Current report | Feb 26, 2025 | Current report | SEC |
| 144 · Notice of proposed sale | Feb 26, 2025 | Other filings | SEC |
| 4 · Change in ownership | Feb 24, 2025 | Insider trade | SEC |
| 424B5 · Prospectus | Feb 20, 2025 | Offer document | SEC |
| 144 · Notice of proposed sale | Feb 20, 2025 | Other filings | SEC |
| 8-K · Current report | Feb 19, 2025 | Current report | SEC |
| FWP · Free writing prospectus | Feb 18, 2025 | Offer document | SEC |
| 4 · Change in ownership | Feb 18, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 18, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 18, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 18, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 18, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 18, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 18, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 18, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 18, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 18, 2025 | Insider trade | SEC |
| SCHEDULE 13G · Big-stake notice | Feb 18, 2025 | Big-stake notice | SEC |
| 424B5 · Prospectus | Feb 18, 2025 | Offer document | SEC |
| S-3ASR · Registration statement | Feb 14, 2025 | Offer document | SEC |
| 10-K · Annual report | Feb 14, 2025 | Annual report | SEC |
| 8-K · Current report | Feb 14, 2025 | Management or board change | SEC |
| 4/A · Change in ownership, amended | Feb 7, 2025 | Insider trade | SEC |
| 8-K · Current report | Feb 5, 2025 | Current report | SEC |
| 8-K · Current report | Jan 31, 2025 | Results | SEC |
| 8-K · Current report | Jan 10, 2025 | Current report | SEC |
| 8-K · Current report | Jan 6, 2025 | Results | SEC |
| 4 · Change in ownership | Jan 3, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 3, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 3, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 18, 2024 | Insider trade | SEC |
| 144 · Notice of proposed sale | Dec 16, 2024 | Other filings | SEC |
| 8-K · Current report | Dec 13, 2024 | Management or board change | SEC |
| S-8 · Registration statement for employee plans | Nov 4, 2024 | Offer document | SEC |
| S-8 · Registration statement for employee plans | Nov 4, 2024 | Offer document | SEC |
| 10-Q · Quarterly report | Nov 4, 2024 | Quarterly report | SEC |
| 8-K · Current report | Oct 30, 2024 | Results | SEC |
This page holds 200 of 1,010 filings. Open Filings
Cap table
Built by 6ix from AbbVie Inc.’s releases · as of Oct 26, 2026
- Common shares
- 1,767,616,306
- Fully diluted
- 1,767,616,306
Fully diluted
| Line | Shares | As of |
|---|---|---|
| Common shares | 1,767,616,306 | Oct 26, 2026 |
Share count over time
| Count | Shares |
|---|---|
| Oct 26, 2026 | 1,767,616,306 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Glenn F Tilton Other companies: Phillips 66 (Director · Since at least May 1, 2012); Corning Incorporated (Director · Nov 30, 2010 – Feb 1, 2012 · Past); Abbott Laboratories (Director · Apr 27, 2007 – Apr 29, 2022 · Past); United Airlines Holdings, Inc. (Director · Feb 1, 2006 – Jun 12, 2013 · Past); Txu Corp (Director · Jan 9, 2006 – Jan 9, 2007 · Past); Lincoln National Corporation (Director · Dec 30, 2005 – Mar 31, 2007 · Past) | Director · Dec 12, 2012 – May 9, 2025 · Past |
| Henry Gosebruch Other companies: ANI Pharmaceuticals, Inc. (Director · Since at least Aug 19, 2026); Neumora Therapeutics, Inc. (President & CEO, Director · Sep 14, 2023 – Feb 14, 2024 · Past); Acelyrin, Inc. (Director · May 4, 2023 – May 21, 2025 · Past); Aptinyx Inc (Director · May 6, 2019 – May 26, 2022 · Past) | EVP, Chief Strategy Officer · Oct 30, 2017 – May 16, 2022 · Past |
| Carlos Albán Other companies: Solventum Corporation (Director · Since at least Apr 1, 2024); SpringWorks Therapeutics Inc (Director · Since at least Jul 14, 2022); Abbott Laboratories (Senior Vice President · Oct 15, 2009 – Dec 1, 2012 · Past) | Vice Chairman · Dec 7, 2012 – Nov 16, 2020 · Past |
| Michael Severino Other companies: Sarepta Therapeutics, Inc. (Chief Executive Officer · Since at least Jul 27, 2026); Viatris Inc. (Director · Since at least May 5, 2025); Avantor, Inc. (Director · Since at least Apr 22, 2020) | Vice Chairman · Jun 2, 2014 – May 23, 2022 · Past |
| Thomas C. Freyman Other companies: Hanger Inc (Director · Nov 14, 2017 – Oct 3, 2022 · Past); Abbott Laboratories (Executive Vice President · Feb 19, 2016 – Jul 29, 2016 · Past); Tenneco Inc (Director · Jul 14, 2015 – Nov 17, 2022 · Past) | Director · Since at least May 8, 2020 |
| Robert J Alpern Other companies: Abbott Laboratories (Director · Since at least Oct 10, 2008); Tricida Inc (Director · Jun 27, 2018 – Nov 23, 2022 · Past) | Director · Since at least Dec 12, 2012 |
| Roxanne Austin Other companies: CrowdStrike Holdings, Inc. (President, Austin Investment Advisors · Since at least Jun 17, 2026); Freshworks Inc. (Director · Since at least Apr 1, 2026) | Director · Since at least May 8, 2026 |
| Roy S Roberts Other companies: Abbott Laboratories (Director · Dec 31, 2005 – Jan 31, 2011 · Past); Burlington Northern Santa Fe Corp (Director · Dec 30, 2005 – Feb 12, 2010 · Past) | Director · Dec 12, 2012 – May 8, 2015 · Past |
| Thomas J. Falk Other companies: Lockheed Martin Corporation (Director · Since at least Jan 30, 2020); Kimberly-Clark Corporation (Executive Chairman, Director · Apr 23, 2019 – Dec 11, 2019 · Past) | Director · Since at least May 9, 2025 |
| William J Chase Other companies: GRAIL, Inc. (Director · Since at least Jun 11, 2024); Intellia Therapeutics, Inc. (Director · Since at least Apr 14, 2023) | EVP, Finance & Administration · Dec 7, 2012 – Jun 26, 2019 · Past |
All 32 people
| Person | Seat |
|---|---|
| Azita Saleki-Gerhardt Other companies: Entegris, Inc. (Director · Since at least May 1, 2019) | EVP, CHIEF OPERATIONS OFFICER · Since at least Feb 20, 2020 |
| Brett J. Hart Other companies: United Airlines Holdings, Inc. (President · Since at least Apr 26, 2016) | President · Since at least May 6, 2016 |
| Edward J. Rapp Other companies: Xos, Inc. (Director · Since at least Aug 20, 2021) | Director · Since at least Mar 31, 2019 |
| Elaine Sorg Other companies: Artiva Biotherapeutics, Inc. (Director · Since at least Feb 18, 2026) | SVP, US COMMERCIAL OPERATIONS · Nov 9, 2020 – Apr 25, 2023 · Past |
| Frederick H. Waddell Other companies: International Business Machines Corporation (Director · Since at least Sep 29, 2023) | Director · Since at least May 3, 2024 |
| Jennifer L Davis Other companies: Procter & Gamble Company (the) (CEO - Health Care · Since at least Apr 1, 2022) | Director · Since at least Oct 11, 2023 |
| Richard A Gonzalez Other companies: Abbott Laboratories (Executive Vice President · Nov 17, 2005 – Apr 6, 2012 · Past) | Director · Dec 7, 2012 – Mar 31, 2025 · Past |
| Adelle Infante | Corporate Communications · Since at least Sep 2, 2026 |
| Brian L Durkin | VP, CONTROLLER · Oct 16, 2018 – Feb 28, 2023 · Past |
| Carrie C Strom | SVP & PRES GLOBAL ALLERG AESTH · May 8, 2020 – May 11, 2023 · Past |
| David Ryan Purdue | SVP, Controller · Since at least Mar 1, 2025 |
| Demetris D Crum | EVP, CHIEF HR OFFICER · Since at least Jul 1, 2025 |
| Jeffrey Ryan Stewart | EVP, CHIEF COMMERCIAL OFFICER · Since at least Nov 9, 2026 |
| Kevin K Buckbee | SVP, CONTROLLER · Mar 1, 2023 – Feb 28, 2025 · Past |
| Melody B. Meyer | Director · Since at least May 9, 2025 |
| Perry C Siatis | EVP, GC AND SECRETARY · Since at least Oct 17, 2022 |
| Rebecca B. Roberts | Director · Since at least May 8, 2026 |
| Robert A. Michael | Chairman of the Board and Chief Executive Officer · Since at least Oct 30, 2026 |
| Susan E Quaggin | Director · Since at least Oct 11, 2023 |
| Thomas J Hudson | SVP, CSO, GLOBAL RESEARCH · Feb 18, 2021 – Feb 28, 2024 · Past |
| Timothy J Richmond | EVP, CHIEF HR OFFICER · Dec 7, 2012 – Feb 28, 2025 · Past |
| William H.L. Burnside | Director · Since at least May 6, 2016 |
Log in to ask 6ix AI your own questions about AbbVie Inc.